434 results on '"Voest, Emile"'
Search Results
2. The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)
3. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
4. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy
5. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)
6. Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol
7. Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
8. Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
9. Supplementary Table S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
10. Supplementary Table S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
11. Supplementary Table S4 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
12. Supplementary Table S4 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
13. Supplementary Table S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
14. Data from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
15. A pan-cancer analysis of the microbiome in metastatic cancer
16. Supplementary Table S5 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
17. Supplementary Table S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
18. Supplementary Table S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
19. Supplementary Figure S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
20. Supplementary Table S5 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
21. Supplementary Figure S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
22. Supplementary Figure S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
23. Agnostic drug development revisited
24. Supplementary Figure S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
25. Data from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
26. Supplementary Figure S4 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
27. Supplementary Figure S4 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
28. Supplementary Table S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
29. Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
30. Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer
31. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
32. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice
33. Impact of genetic counselling strategy on diagnostic yield and workload for genome sequencing-based tumour diagnostics
34. Precision cancer medicine: Concepts, current practice, and future developments
35. Abstract IA013: A zebrafish model for VHL and hypoxia signaling
36. Phase II study ( KAMELEON ) of single‐agent T‐DM1 in patients with HER2 ‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
37. Supplementary Materials and Methods from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity
38. Data from AACR Project GENIE: Powering Precision Medicine through an International Consortium
39. Supplementary Figures 1-11 from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity
40. Table S3 from AACR Project GENIE: Powering Precision Medicine through an International Consortium
41. Data from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
42. Supplementary Figure 4 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
43. Table S4 from AACR Project GENIE: Powering Precision Medicine through an International Consortium
44. Supplementary Figure 5 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
45. Data from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity
46. Table S4 from AACR Project GENIE: Powering Precision Medicine through an International Consortium
47. Supplementary Figure 1 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
48. Supplementary Table 1 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
49. Supplementary Table 4 from Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity
50. Supplementary Figure 3 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.